PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Summary

RATIONALE: Heat shock protein (HSP)90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. PURPOSE: This phase II trial is studying how well hsp90 inhibitor STA-9090 works as second- or third-line therapy for the treatment of patients with metastatic pancreatic cancer.

Timeline

Start

2010-12

Primary completion

2013-05

Completion

2013-05

Drugs

Indications